Who is developing what with whom, per the filing. In its annual report for fiscal 2020, filed February 16, 2021, CRISPR Therapeutics describes its most advanced program, CTX001, as a gene-editing candidate it is developing in collaboration with Vertex Pharmaceuticals. The structure matters more than the headline: this is a partnered asset, not a wholly owned one.

For a company whose value sits heavily on a single lead program, the collaboration framing is the load-bearing disclosure. A shared development-and-commercialization arrangement means the upside is split — and that the partner carries weight in decisions about how the program advances. The 10-K presents CTX001 as still in clinical development, not as an approved product.

“CTX001 is being developed under a co-development and co-commercialization agreement between us and Vertex Pharmaceuticals Incorporated, or Vertex.”— CRISPR Therapeutics AG, Form 10-K (FY2020) source

The filing dates the relationship and traces how its economics were built up over time, which is what a deals desk reads it for. The companies "established our initial collaboration agreement in 2015," the 10-K states, "which focused on TDT, SCD, cystic fibrosis and select additional indications." Under that 2015 agreement, per the filing, CRISPR "agreed to provide technology and options to obtain licenses relating to our CRISPR/Cas technology to Vertex in exchange for a $75.0 million upfront payment," and "Vertex also made a $30.0 million equity investment in us." That sets the original price of admission to the partnership: a license-option payment plus an equity stake.

The structure tightened around CTX001 specifically two years later. "In December 2017," the 10-K says, "we entered into a joint development and commercialization agreement with Vertex to co-develop and co-commercialize CTX001 as part of that collaboration." The economic consequence is the disclosure a model leans on: per the filing, "Vertex exercised its option to co-develop and co-commercialize the hemoglobinopathies program for which net profits and losses, as applicable, will be shared equally by the parties." A 50/50 profit-and-loss split is the defining number of the arrangement — it is exactly why the program is not wholly owned, and why CRISPR's eventual economics on its lead asset are halved by design.

The collaboration was then widened in 2019 into new disease areas on different terms, and the contrast between the two structures is instructive. "On June 6, 2019, we and Vertex entered the 2019 Collaboration Agreement," the filing states, under which "Vertex will be responsible for development and commercialization activities." For that agreement, "we received a $175.0 million up-front payment from Vertex," CRISPR reports, and "we are eligible to receive milestone payments from Vertex of up to $825.0 million in the aggregate, depending on the numbers and types of products that achieve pre-determined development and commercial milestones," plus "royalties on the sales of products ranging from the low single digits to the low double digits." That is the more conventional licensor structure — upfront, milestones, royalties — sitting alongside the 50/50 hemoglobinopathies split, with an option for CRISPR to convert specified programs back to a 50/50 cost-and-profit footing.

The filing also spells out a mechanic that matters to anyone modeling who captures what under the equal split, and it is the kind of clause a deals desk looks for in any co-development structure: an exit ramp from the 50/50 economics. Per the 10-K, where a party exercises an opt-out, "the party opting-out will no longer share in the net profits and net losses associated with such product candidate and, instead, the opting out party will be entitled to high single to mid-teen percentage royalties on the net sales of such product, if commercialized." That single provision converts a co-owner into a royalty recipient at a defined rate band, and it is the hinge a model uses to scenario the two ways the partnership can resolve: shared profits and shared losses on one path, a capped royalty with no loss exposure on the other. For a single-lead-program company, which of those two outcomes prevails on CTX001 is among the most consequential financial questions in the filing.

The 2015 agreement's architecture is worth reading alongside the headline payments, because it shows the relationship was built as an options platform rather than a single transaction. Under that agreement, the filing states, the parties pursued "further discovery efforts focused on a specified number of other genetic targets," and "Vertex had the option to exclusively license treatments for a specified number of collaboration targets that emerged from the four-year research collaboration." An options-and-discovery framework of that kind is why the economics accreted in layers over time: the 2015 upfront and equity bought access and option rights; the 2017 joint development and commercialization agreement converted the hemoglobinopathies option into the 50/50 program around CTX001; and the 2019 agreement added new disease areas on the more conventional upfront-milestone-royalty terms. A model reads that progression as a staged build-up of partner economics, each stage with its own structure, rather than one deal restated.

The deals-desk read is to separate ambition from cash. The partnership de-risks the program financially — a larger, well-capitalized partner shares the cost of an expensive, novel modality — but it also means CRISPR does not capture the full economics of any eventual success: half of hemoglobinopathies profits flow to Vertex by the terms above, and the 2019-agreement programs convert CRISPR into a milestone-and-royalty recipient rather than a co-owner unless it opts in. That trade-off is the essence of the arrangement as the filing lays it out.

Read forward from early 2021, the open question is execution: whether a clinical-stage, partnered gene-editing candidate can move through development toward approval, and what the shared structure ultimately delivers to each side. The 2020 10-K does not answer that — it documents the partnership, and its layered economics, as they stand at the time of filing.

Every figure above is drawn from the company's primary SEC filing — surfaced through SEC filings, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.